FMP

FMP

Enter

ZTS - Zoetis Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ZTS.png

Zoetis Inc.

ZTS

NYSE

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

157.44 USD

1.79 (1.14%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

6.67B

7.78B

8.08B

8.54B

9.26B

10.05B

10.92B

11.86B

12.88B

13.99B

Revenue %

-

16.49

3.91

5.74

8.33

8.62

8.62

8.62

8.62

Ebitda

2.69B

3.17B

3.36B

3.69B

3.87B

4.17B

4.53B

4.92B

5.35B

5.81B

Ebitda %

40.24

40.79

41.56

43.13

41.83

41.51

41.51

41.51

41.51

Ebit

2.25B

2.72B

2.89B

3.19B

3.38B

3.59B

3.89B

4.23B

4.59B

4.99B

Ebit %

33.63

35.03

35.8

37.38

36.46

35.66

35.66

35.66

35.66

Depreciation

441M

448M

465M

491M

497M

587.93M

638.61M

693.66M

753.46M

818.4M

Depreciation %

6.61

5.76

5.75

5.75

5.37

5.85

5.85

5.85

5.85

Balance Sheet

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Total Cash

3.6B

3.48B

3.58B

2.04B

1.99B

3.79B

4.11B

4.47B

4.85B

5.27B

Total Cash %

53.96

44.78

44.27

23.86

21.45

37.66

37.66

37.66

37.66

Receivables

1.01B

1.13B

1.22B

1.3B

1.32B

1.49B

1.62B

1.76B

1.91B

2.08B

Receivables %

15.18

14.57

15.04

15.26

14.22

14.85

14.85

14.85

14.85

Inventories

1.63B

1.92B

2.35B

2.56B

2.31B

2.68B

2.91B

3.16B

3.43B

3.72B

Inventories %

24.39

24.73

29.02

30.01

24.91

26.61

26.61

26.61

26.61

Payable

457M

436M

405M

411M

433M

541.99M

588.71M

639.45M

694.57M

754.45M

Payable %

6.85

5.61

5.01

4.81

4.68

5.39

5.39

5.39

5.39

Cap Ex

-453M

-477M

-586M

-732M

-655M

-720.2M

-782.28M

-849.71M

-922.96M

-1B

Cap Ex %

-6.79

-6.13

-7.25

-8.57

-7.08

-7.16

-7.16

-7.16

-7.16

Weighted Average Cost Of Capital

Price

157.44

Beta

Diluted Shares Outstanding

454.85M

Costof Debt

3.92

Tax Rate

After Tax Cost Of Debt

3.11

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

6.74B

Total Equity

71.61B

Total Capital

78.36B

Debt Weighting

8.61

Equity Weighting

91.39

Wacc

7.84

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

6.67B

7.78B

8.08B

8.54B

9.26B

10.05B

10.92B

11.86B

12.88B

13.99B

Ebitda

2.69B

3.17B

3.36B

3.69B

3.87B

4.17B

4.53B

4.92B

5.35B

5.81B

Ebit

2.25B

2.72B

2.89B

3.19B

3.38B

3.59B

3.89B

4.23B

4.59B

4.99B

Tax Rate

20.65

20.65

20.65

20.65

20.65

20.65

20.65

20.65

20.65

20.65

Ebiat

1.84B

2.23B

2.3B

2.55B

2.68B

2.89B

3.14B

3.41B

3.7B

4.02B

Depreciation

441M

448M

465M

491M

497M

587.93M

638.61M

693.66M

753.46M

818.4M

Receivables

1.01B

1.13B

1.22B

1.3B

1.32B

1.49B

1.62B

1.76B

1.91B

2.08B

Inventories

1.63B

1.92B

2.35B

2.56B

2.31B

2.68B

2.91B

3.16B

3.43B

3.72B

Payable

457M

436M

405M

411M

433M

541.99M

588.71M

639.45M

694.57M

754.45M

Cap Ex

-453M

-477M

-586M

-732M

-655M

-720.2M

-782.28M

-849.71M

-922.96M

-1B

Ufcf

-353.66M

1.77B

1.65B

2.01B

2.79B

2.32B

2.68B

2.91B

3.16B

3.44B

Wacc

7.84

7.84

7.84

7.84

7.84

Pv Ufcf

2.15B

2.3B

2.32B

2.34B

2.36B

Sum Pv Ufcf

11.47B

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

7.84

Free Cash Flow T1

3.57B

Terminal Value

92.92B

Present Terminal Value

63.7B

Intrinsic Value

Enterprise Value

75.17B

Net Debt

4.76B

Equity Value

70.41B

Diluted Shares Outstanding

454.85M

Equity Value Per Share

154.8

Projected DCF

154.8 -0.017%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep